DPP-IV inhibitors (Santhera)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameDPP-IV inhibitors (Santhera)
Drug Alias NameDPP-IV inhibitors (Biovitrum)dipeptidyl-peptidase IV inhibitors (Santhera)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenGermany
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGraffinity Pharmaceuticals AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanthera PharmaceuticalsGraffinity Pharmaceuticals AGSwedish Orphan Biovitrum Ab (Publ)
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A